Drug Administration Routes Impact the Metabolism of a Synthetic Cannabinoid in the Zebrafish Larvae Model
1Department of Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) and Department of Pharmacy, Saarland University, Campus E8 1, 66123 Saarbrücken, Germany; Yu-Mi.Park@helmholtz-hips.de
2Environmental Safety Group, Korea Institute of Science and Technology (KIST) Europe, 66123 Saarbrücken, Germany
3Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS), Saarland University, 66421 Homburg, Germany; m.r.meyer@mx.uni-saarland.de
4German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig Germany, 38124 Braunschweig, Germany
*Correspondence: Rolf.Mueller@helmholtz-hips.de (R.M.); Jennifer.Herrmann@helmholtz-hips.de (J.H.); Tel.: +49-0681-98806-3000 (R.M.); +49-0681-98806-3101 (J.H.)Abstract
Zebrafish (Danio rerio) larvae have gained attention as a valid model to study in vivo drug metabolism and to predict human metabolism. The microinjection of compounds, oligonucleotides, or pathogens into zebrafish embryos at an early developmental stage is a well-established technique. Here, we investigated the metabolism of zebrafish larvae after microinjection of methyl 2-(1-(5-fluoropentyl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamido)-3,3-dimethylbutanoate (7′N-5F-ADB) as a representative of recently introduced synthetic cannabinoids. Results were compared to human urine data and data from the in vitro HepaRG model and the metabolic pathway of 7′N-5F-ADB were reconstructed. Out of 27 metabolites detected in human urine samples, 19 and 15 metabolites were present in zebrafish larvae and HepaRG cells, respectively. The route of administration to zebrafish larvae had a major impact and we found a high number of metabolites when 7′N-5F-ADB was microinjected into the caudal vein, heart ventricle, or hindbrain. We further studied the spatial distribution of the parent compound and its metabolites by mass spectrometry imaging (MSI) of treated zebrafish larvae to demonstrate the discrepancy in metabolite profiles among larvae exposed through different administration routes. In conclusion, zebrafish larvae represent a superb model for studying drug metabolism, and when combined with MSI, the optimal administration route can be determined based on in vivo drug distribution.
1. Introduction
Zebrafish (Danio rerio; ZF) has become a very prominent in vivo model organism in various research fields, such as toxicology, drug discovery, disease models, and neurobiology [1,2,3,4,5]. This has several reasons, such as ease of handling, predictivity of ZF assays, and their link to effects observed in humans. Importantly, the ZF genome shares 70% similarity to human genes and the similarity of potential human disease-related genes is even higher (82%) [6,7,8].
The use of self-feeding ZF embryos and larvae that are younger than 120 h post-fertilization (hpf) is particularly popular because such experiments are not considered as animal experiments according to European legislation (EU directive 2010/63/EU). Thus, experiments with larvae at ≤120 hpf are in compliance with the 3R principle (Replacement, Reduction, Refinement) as they contribute to the reduction of animal experiments. Consequently, ZF embryos and larvae have been widely applied in studies of e.g., human disease [9,10], infection [11,12], antibiotics [13,14], and human metabolism [15,16,17], to name just a few.
Microinjection has been used already for decades as a way of administering compounds to fish in early life stages, and this technique is still widely used in cellular microbiological research [18,19,20]. However, most laboratories use aquatic exposure in screening campaigns with ZF larvae, thus neglecting the potentially hindered uptake and absorption of lipophilic compounds which, in turn, can lead to a rather high rate of false negatives. More recently, some groups proposed to administer lipophilic compounds via microinjection into yolk sac due to easy and straightforward microinjection protocols that can be automated if required [21,22,23].
In an earlier study [24], we detected only one metabolite in ZF larvae after microinjection of a new psychoactive substance (NPS) into the yolk sac. In contrast, 18 metabolites were detected when we administered the compound to the ZF larvae through conventional aquatic exposure. This unexpected result prompted us to refine our protocols for metabolite identification in ZF larvae as part of our preclinical DMPK (drug metabolism and pharmacokinetics) assay pipeline.
The common sites for ZF microinjection are yolk sac, caudal vein, heart ventricle, and hindbrain. The corresponding techniques require different levels of expertise, with yolk sac injections being the simplest technique. However, more advanced microinjection techniques, such as caudal vein injections, provide the advantage of ensuring proper systemic distribution of a drug or other microinjected agents. For studying drug metabolism in ZF larvae, this appears to be crucial as test compounds need to reach the liver compartment where most metabolic reactions take place. Metabolic processing is mainly performed by cytochrome P450 (CYP) enzymes, and ZF larvae possess a full complement of CYP genes, which display functional similarity to the human orthologs. This similarity makes ZF a very promising model as its predictive value in comparison to human metabolism is thought to be high [25,26].
The spatial distribution of a drug can be checked by mass spectrometry imaging (MSI) as an outstanding visualization tool that enables label-free imaging in biological tissues. Here, we applied MSI in order to understand the distribution of a drug and its metabolites in ZF larval bodies, which, in turn, enables an informed choice on the optimal administration route. However, sample preparation of ZF larvae sections is still challenging.
In this study, we present a new approach of employing various administration routes for drug exposure to ZF larvae to further improve metabolite identification resulting in a spectrum, which is widely in concordance with human metabolism. A new synthetic cannabinoid (SC), methyl 2-(1-(5-fluoropentyl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamido)-3,3-dimethylbutanoate (7′N-5F-ADB, Figure 1), was chosen for this study because it appeared recently on the illicit drug market [27] as one of the most dangerous SCs with high potency and serious adverse effects resulting in hospitalizations and fatalities [28,29,30,31]. To characterize the circulation of 7′N-5F-ADB and its metabolites in the ZF larval body, the spatial distribution was visualized by matrix-assisted laser desorption/ionization (MALDI)-MSI as an emerging technique enabling the imaging of molecular species [32,33,34].
2. Results and Discussion
2.2. The Spatial Distribution of 7′N-5F-ADB in ZF Larva Is Visualized by MALDI-MSI
Mass spectrometry imaging (MSI) combined with MALDI enables coupling of high mass resolution data with visualized images of sample sections. Due to the results from metabolite detection following different administration routes for 7′N-5F-ADB into ZF larvae, we concluded that the drug distribution differs significantly if the NPS is given through the water, microinjected into yolk sac, or microinjected into caudal vein, heart ventricle, and hindbrain. Thus, MALDI-MSI was used to study the distribution of the parent compound 7′N-5F-ADB in the ZF larval bodies. To our knowledge, this is the first concise study of drug distribution in ZF larvae following different routes of compound microinjection.
After 1-day exposure through medium, only 7′N-5F-ADB could be detected via MSI of sections of ZF larvae, and the parent compound exclusively accumulated inside the yolk sac. Therefore, we prepared ZF larvae that were treated for an extended period, from two days post-fertilization (dpf) to five dpf. In sections from these ZF larvae, we found the parent compound to be better distributed than in sections of one-day treated ZF larvae (Figure 6a,b). In summary, 7′N-5F-ADB and two major metabolites (M5 and M13; Figure 6c,d) appeared in dorsal and ventral regions at high abundances after 3 d treatment through aquatic exposure, but corresponding masses could not be detected in the tail end area of ZF larva.
In contrast, it was not possible to generate distribution images of the parent compound and M13 in ZF larvae that were treated by microinjecting into caudal vein, heart ventricle, and hindbrain (Table 3), and M5 was identified in only one section among heart ventricle samples. This might be indicative of a fast distribution and an accordingly fast metabolism. We thus analyzed the spatial distribution of other major metabolites and compared their distribution to MSI data from ZF larvae that were exposed to 7′N-5F-ADB through water. We were able to image five metabolites from microinjected ZF larvae, all of which were structural isomers as determined by LC-HRMS/MS: M8/M9 (two isomers at m/z 378.2013), M10/M11/M12 (three isomers at m/z 380.1970), M16/M17 (two isomers at m/z 394.2126), M18/M19/M20 (three isomers at m/z 396.1919), and M23/M24/M25/M26 (four isomers at m/z 410.2075). The main metabolites that we could visualize by MSI are also listed in Table 3, and exemplary images of the isomers M23/M24/M25/M26 from larvae that were exposed through microinjection into different organs are depicted in Figure 7. Interestingly, depending on the route of administration, the images show distinct distribution patterns inside the larval bodies. In the caudal vein slices, the metabolite was detected along the dorsal aorta and concentrated in the veins and arteries of ZF larva. ZF larva microinjected into heart ventricle showed full spread of M23/M24/M25/M26 from head region to tail region, and high concentrations were found throughout the larval body. In contrast, hindbrain slices indicated the best distribution of this metabolite at intermediate concentrations. Images of these isomeric metabolites visualized by MALDI-MSI are represented as the summed distribution of the multiple isomers, as these constitutional and isobaric isomers cannot be distinguished due to lack of chromatographic separation in MSI. However, the presence of several isomers probably improved mass detection and imaging above the method detection limit (MDL).
In the MSI study, we observed a certain discrepancy when we compared the detection of metabolites from LC-HRMS/MS and MSI. Although MSI is a highly sensitive method at trace level, it could not detect the masses in some cases that were clearly detected by LC-HRMS/MS in pooled larvae samples. This effect was caused by the spatial distribution of lower abundant metabolites in the ZF larva and their further dilution due to the preparation of on average more than ten cryosectioned slices per larva. In particular, several metabolites, including M5 and M13, from microinjected ZF larvae were confirmed by LC-HRMS/MS, but it was not possible to generate MS images displaying a specific pattern. Further studies to improve the MDL of MALDI-MSI for the analysis of ZF larvae are ongoing. In summary, the treatment of ZF larvae with 7′N-5F-ADB through aquatic exposure resulted in a strong accumulation of the lipophilic NPS in the yolk sac, thus, protecting the compound from being metabolized in metabolically active organs. In contrast, when 7′N-5F-ADB was microinjected into vital organs of the ZF larvae, this resulted in the fast distribution and metabolism of the drug, as demonstrated by LC-HRMS/MS and MSI measurements. Furthermore, the finding was confirmed by the spatial distribution analysis of 7′N-5F-ADB and its metabolites in ZF larvae treated via microinjection.
We could demonstrate the importance of choosing the right administration route when studying drug metabolism in ZF larvae, also taking the chemical properties of the investigated compound into consideration. Here, the lipophilic nature of 7′N-5F-ADB hindered its proper distribution inside the larval bodies when given through water or when microinjected into the yolk sac. Intriguingly, we could observe a large number of (human) phase I and phase II metabolites at relatively high abundance when we microinjected the NPS into organs that support faster distribution, such as the heart ventricle. Moreover, the MS images showed distinct distribution patterns of its metabolites throughout the ZF larva body, which might be linked in future studies to potential toxic effects of compounds and their in vivo metabolites. Further studies are in progress to refine protocols for the cryosectioning of ZF larva and subsequent MSI experiments as it appears to be crucial to initially investigate compound distribution before proceeding to metabolite identification and to general pharmacological studies.
3. Materials and Methods
3.1. Chemicals and Other Materials
7′N-5F-ADB was obtained from www.buyresearchchemicals.de tagged as 4′N-5F-ADB. However, NMR (nuclear magnetic resonance) studies confirmed it to be 7′N-5F-ADB. Dimethyl sulfoxide (DMSO), methylene blue, phenol red, tricaine (3-amino-benzoic acid ethyl ester), mineral oil, trifluoroacetic acid, gelatin from cold water fish skin, and 2,5-dihydroxybenzoic acid were obtained from Sigma-Aldrich (Taufkirchen, Germany). Methanol (LC-MS grade), acetonitrile (LC-MS grade), formic acid (LC-MS grade) were from VWR (Darmstadt, Germany). NaCl, KCl, MgSO4, Ca(NO3)2, and HEPES were obtained from Carl Roth (Karlsruhe, Germany). The 10 mM stock solution of 7′N-5F-ADB was prepared in DMSO and it was stored for a maximum of one month at −20 °C. The working solutions of 7′N-5F-ADB were freshly prepared prior to each experiment. Cell culture flasks, 24-well plates, and 6-well plates were purchased from Sarstedt (Nümbrecht, Germany). Basal hepatic cell medium MIL 700C and differentiation medium supplement with antibiotics ADD 720C were from Biopredic International (Saint-Grégoire, France). Glass capillaries TW100F-4 [4 inch (100 mm), 1/0.75 OD/ID (mm), Filament] were obtained from World Precision Instruments Germany GmbH (Friedberg, Germany). Undifferentiated HepaRG cells (HPR101) were purchased from Biopredic International (under MTA agreement No: 10528AHR10, Saint-Grégoire, France). Conductive indium-tin-oxide (ITO) coated glass slides were obtained from Bruker Daltonics (Bremen, Germany). ZF embryos of the AB wild-type line were initially obtained from the Luxembourg Center for Systems Biomedicine (Belvaux, Luxembourg). Dry small granulate food was purchased from SDS Deutschland (Limburgerhof, Germany), and Artemia cysts (>230,000 nauplii per gram) were obtained from Coralsands (Wiesbaden, Germany).
3.2. Zebrafish Maintenance and Embryo Collection
ZF husbandry and all experiments with ZF larvae were carried out in accordance with EU Directive 2010/63/EU and the German Animal Welfare Act (§11 Abs. 1 TierSchG). All works were performed following internal standard-operating procedures (SOPs) based on published standard methods [38].
Adult zebrafish for breeding were kept in an automated aquatic eco-system (PENTAIR, Apopka, UK). The following parameters are continuously monitored: Temperature (27 ± 0.5 °C), pH (7.0 ± 0.1), conductivity (800 ± 50 µs), and light-dark cycle (14 h/10 h). Fish were fed twice a day with dry small granulate food and additionally once a day with freshly hatched live Artemia cysts. The ZF embryo medium (0.3× Danieau’s solution) consisted of 17 mM NaCl, 2 mM KCl, 0.12 mM MgSO4, 1.8 mM Ca(NO3)2, 1.5 mM HEPES, pH 7.1–7.3, and 1.2 µM methylene blue. For ZF embryo production, AB wild-type line pairs were kept overnight in standard mating cages, separated by gender. In the following morning, the separators were removed, and the zebrafish spawned immediately. Fertilized eggs of zebrafish were selected using a LEICA M205 FA stereo microscope (Leica Mikrosysteme Vertrieb GmbH, Wetzlar, Germany), and embryos were raised in an incubator at 28 °C with daily medium change and cleaning of embryo cultures. ZF larvae at 4 dpf were used for drug metabolism studies.
3.3. Drug Treatment of ZF Larvae via Aquatic Exposure
The sample preparation following aquatic drug exposure is described in detail in a study by Richter et al. [24]. A non-toxic exposure concentration was chosen based on the survival rate as determined in in vivo maximum-tolerated concentration (MTC) experiments with 4 dpf ZF larvae. For metabolite studies, ten ZF larvae at 4 dpf were transferred to one well of a 6-well plate containing 3 mL of Danieau’s medium with 50 µM 7′N-5F-ADB and a final concentration of 1% (v/v) DMSO, and ZF larvae were treated for 24 h in an incubator at 28 °C. Additional ten larvae were incubated in compound-free medium containing 1% (v/v) DMSO that served as negative control (background masses). Prior to sample extraction, ten larvae were pooled, and sample extractions were performed as described below (Section 3.5). All samples were prepared in six replicates.
3.4. Drug Treatment of ZF Larvae via Microinjection into Different Compartments
The glass microneedle for microinjection was prepared by a Flaming/Brown type micropipette puller (Model P-100, Sutter Instrument, Novato, CA, USA) using the following settings: heat: ramp value ± 10, pull: 80, velocity: 60, delay time: 90 ms, and pressure: 13.8 bar. For injections, a 5 mM solution of 7′N-5F-ADB was prepared in 50% (v/v) DMSO and 50% (v/v) of a 0.5% phenol red solution. The injection needle was filled with 10 µL of 5 mM 7′N-5F-ADB without air bubbles by a microloader pipette tip and it was placed in a M-152 manipulator (Narishige Group, Tokyo, Japan) connected to a FemtoJet 4× Microinjector (Eppendorf, Hamburg, Germany). Before microinjection, all microinjection needles were calibrated by single droplet injections onto mineral oil on a micrometer slide. The injection volume (nL) was calculated according to the sphere volume equation (V = πγ3 4/3) based on the diameter (mm) of the droplet [39,40]. We have chosen to microinject 4.19 nL of 5 mM 7′N-5F-ADB per larvae, which corresponds to a total amount of 284.4 ng in a pool of 36 larvae.
ZF larvae at 4 dpf were anaesthetized by tricaine and then they were lined up on an agarose plate prepared using Z-MOLD (World Precision Instruments, Sarasota, USA). Excess medium was removed with a pipette. Microinjections were done into three different compartments of ZF larvae (caudal vein, heart ventricle, and hindbrain; Figure 9) under a stereo microscope (LEICA M205 FA stereo microscope). Larvae were directly transferred to fresh Danieau’s medium and they were incubated at 28 °C for 1 h. Prior to sample extraction, 36 larvae were pooled. Sample extractions were performed as described below (Section 3.5). All samples were prepared in triplicates. The mortality rate of ZF larvae after microinjection was below 10% in all cases.
3.7. MSI Analysis of ZF Larva by MALDI-FT-ICR
Treated ZF larvae (see Section 3.3 and Section 3.4) were directly frozen after embedding in 40% (w/v) gelatin solution and samples were stored at –20 °C until cryosectioning. Cuts with 10-µm thickness from single larvae were prepared using a cryostat (MEV; SLEE, Mainz, Germany) and they were put on a cold conductive indium-tin-oxide (ITO) coated glass slide. After scanning slides under a microscope to align the optical image of the sample in MALDI, the serial sections from one larva were deposited using TM-Sprayer (HTX M5; HTX Technologies, NC, USA) with 15 mg mL−1 2,5-dihydroxybenzoic acid (2,5-DHB) in acetonitrile:water (9:1, v/v) containing 0.1% of trifluoroacetic acid, and then dried in a vacuum desiccator for 2 h. The dried glass slide was stored at –20 °C before MSI measurement.
MSI analysis was performed using MALDI and 7.0T SolariX FT-ICR (Bruker Daltonics, Bremen, Germany) in positive ion mode (m/z range 150–1,000), using 40 laser shots per pixel with a raster width of 20 µm. For auto-calibration of MALDI of each laser measurement, lock mass was set to m/z 273.039364 (2,5-DHB matrix), and mass calibration of FT-ICR was carried out using the calibration solution according to the manufacturer’s manual. All MALDI-MSI data acquisitions and image analyses in two dimensions were processed using ftmsControl version. 2.2, flexImaging version 5.0, and SCiLS Lab version 2019b Pro softwares (Bruker Daltonics, Bremen, Germany).
4. Summary and Conclusions
ZF larvae were exposed to 7′N-5F-ADB by different administration routes and the total number of metabolites observed in these microinjected samples was higher than the number of metabolites detected after conventional waterborne exposure (Table 1). The only exception was the ZF larvae sample, where the NPS was microinjected into yolk sac. Here, only one metabolite was found [24], which we could later explain by the compound’s lack of distribution in metabolically active organs of the larvae. Furthermore, the spatial distribution of 7′N-5F-ADB and its metabolites was investigated in detail by MSI and we found significant differences following aquatic exposure and microinjection into different organs (Figure 6 and Figure 7).
Comparing the metabolite pattern from all investigated models (human [27], HepaRG cells, ZF larvae) using LC-HRMS/MS, metabolite M5, formed by ester hydrolysis, was among the most abundant peaks in human samples, HepaRG cells, and all ZF larvae samples prepared in this study. The parent compound was detected in high amounts in all samples except human urine samples, and the metabolites listed as next most abundant were M4 (oxidative defluorination of M5), M30 (glucuronidation of M5), M11 (hydroxylation of M5 in the tertiary butyl part), M13 (oxidation defluorination in combined with oxidation to carboxylic acid), and M16 (hydroxylation of the fluoro pentyl chain isomer 1) (Table 2). These results suggest that the major metabolites were produced sequentially from M5 and the main metabolic reactions were oxidation and hydroxylation as part of phase I metabolism. Interestingly, most of the glucuronidated conjugate metabolites found in human urine were also detected in significant amounts in microinjected ZF larvae (Table 1, Figure 5, Supplementary Figures S1 and S5). Fifteen phase I and phase II metabolites were commonly observed in the three models, which were generated by amide hydrolysis, ester hydrolysis, hydroxylation of the alkyl chains, and glucuronidation (Figure 3a and Table 1).
Remarkably, microinjected ZF larvae had a high concordance rate of 70% to human urine samples, compared to only 55% concordance of HepaRG cell metabolites to human metabolites (Figure 3b). While comparing the mutual similarity of metabolism among the three investigated models, ZF larvae were able to generate four metabolites also found in human urine, which were, however, not detected in HepaRG cells. Encouragingly, 18 out of 20 HepaRG metabolites were also found in ZF larvae, which included 15 compounds that were detected in all three models. It is noteworthy that it could be shown again that ZF larvae produce a metabolite spectrum which is highly similar to human in vitro and in vivo metabolism. Furthermore, the metabolic pathway of 7′N-5F-ADB [24,27] was refined and extended by addition of the results from ZF larvae and HepaRG cells (Figure 5).
Taken together, among the studied models, microinjected ZF larvae generated a high number of metabolites and the most authentic spectrum of human metabolites of 7′N-5F-ADB. Intriguingly, metabolic reactions could be observed already within one hour after microinjection. In contrast, at least 24 h waterborne treatment of ZF larvae was necessary to identify most common metabolites.
Due to its ease of handling and flexibility when it comes to the administration route of compounds, and because of being in accordance with results from human metabolism studies, the ZF larvae model is an excellent in vivo tool for drug metabolism and distribution studies. This is also owing to the fact that we could successfully prepare MS images of treated larvae, which allows us to rationally choose an appropriate route for compound administration. Although further optimization of MSI applied to ZF larvae [33] and the generation of metabolite images need to be done, it is already a unique tool to get a first impression on the distribution of a drug and its metabolites depending on the route of administration. Here, microinjection in vital organs, such as the heart ventricle, appeared to be most beneficial to achieve fast distribution and metabolism of the highly lipophilic 7′N-5F-ADB.
Acknowledgments
The authors would like to thank Mi Sun Park for the pictures of zebrafish larvae and Katarina Cirnski, Anastasia Andreas, Susanne Kirsch-Dahmen, and Lea Wagmann for skillful technical support and fruitful discussion.
Appendix Group
Supplementary Materials
The following are available online, Figure S1: Detection profile of seventeen minor metabolites of 7′N-5F-ADB found in ZF larvae injected into three different organs (caudal vein, heart ventricle, and hindbrain), Figure S2: Internal amount-time profile of five main metabolites (M4, M5, M10, M11, and M30) in HepaRG cells incubated with 20 µM 7′N-5F-ADB (n = 2), Figure S3: The effects of exposure time and concentration on the formation of five main metabolites [M4, M5, M10, M11, and M30; from (a) to (e)] in HepaRG cells. The main metabolic pathway in HepaRG cells was identified (f), Figure S4: MS2 spectra of 11 out of 24 metabolites detected in zebrafish larvae exposed by 7′N-5F-ADB, arranged by mass, Figure S5: Schematic representation of 7′N-5F-ADB phase I and phase II metabolites in humans, ZF larvae, and HepaRG cells, Table S1: Detailed information of 7′N-5F-ADB and its phase I and phase II metabolites in all investigated models.
Funding
This research was funded in part by KIST Europe Basic Fund Signature Research (Project # 12001).
Conflicts of Interest
The authors declare no conflict of interest.
| Compound | Human Screening Data [27] | Zebrafish Larvae, Published Data [24] | Zebrafish Larvae, Data from This Study | HepaRG In Vitro Model | |||||
|---|---|---|---|---|---|---|---|---|---|
| Plasma | Urine | Aquatic Exposure | Microinjection | ||||||
| Yolk Sac | Caudal Vein | Heart Ventricle | Hindbrain | ||||||
| Parent compound | 7′N-5F-ADB | +++ | + | +++ | ++ | ++ | ++ | ++ | +++ |
| Phase I | M1 | + | + | + | + | + | + | ||
| M2 | + | + | + | ||||||
| M3 | + | + | + | + | + | ||||
| M4 | + | + | + | + | + | + | |||
| M5 | ++ | +++ | ++ | + | + | + | ++ | ||
| M6 | + | + | + | + | + | + | |||
| M7 | + | + | + | + | + | ||||
| M8 | + | + nq | + nq | + nq | |||||
| M9 | + nq | + nq | + nq | ||||||
| M10 | + | + | + | + | + | + | |||
| M11 | + | ++ | + | + nq | + | + | |||
| M12 | + | + | + | + nq | + | + | |||
| M13 | + | + | +++ | +++ | +++ | +++ | + | ||
| M14 | + | ||||||||
| M15 | + | + | + | + | + | ||||
| M16 | + | + | + | + | + | + | |||
| M17 | + | + | + | + | + | + | |||
| M18 | + | ||||||||
| M19 | + | ||||||||
| M20 a | |||||||||
| M21 | + | + | + | + | + | ||||
| M22 | + | ||||||||
| M23 | + c | + b | + b | + b | |||||
| M24 | + c | ||||||||
| M25 | + c | ||||||||
| M26 | |||||||||
| Total number of Phase I metabolites | 4 | 17 | 14 | 1 | 17 | 17 | 17 | 15 | |
| Phase II | M27 | + | + | + | + | + | |||
| M28 | + | + | + nq | + | |||||
| M29 | + | + | + | + | + | ||||
| M30 | + | + | + | + | + | + | |||
| M31 | + | + | + | + | + | ||||
| M32 | + | ||||||||
| M33 | + | ||||||||
| M34 | + | + | + | + | |||||
| M35 | + c | +c | + b | + b | + b | + b | |||
| M36 | + c | +c | |||||||
| Total number of Phase II metabolites | - | 10 | 4 | - | 7 | 6 | 7 | 5 | |
| Total number of detected Phase I/II metabolites | 4 | 27 | 18 | 1 | 24 | 23 | 24 | 20 | |
| Human Screening Data [27] | Zebrafish Larvae, Published Data [24] | Zebrafish Larvae, Data from this Study | HepaRG In Vitro Model | |||||
|---|---|---|---|---|---|---|---|---|
| Plasma | Urine | Aquatic Exposure † | Microinjection †† | |||||
| Yolk Sac | Caudal Vein | Heart Ventricle | Hindbrain | |||||
| most abundant peak | P | M5 | P | M13 | M13 | P | M13 | P |
| second most abundant peak | M5 | M11 | M5 | P | P | M5 | P | M5 |
| third most abundant peak | M16 | M30 | M13 | -* | M5 | M13 | M5 | M4 |
| Aquatic Exposure | Microinjection † | ||||
|---|---|---|---|---|---|
| 1-Day Exposure (from 4 dpf to 5 dpf) | 3-Day Exposure (from 2 dpf to 5 dpf) | Caudal Vein | Heart Ventricle | Hindbrain | |
| most abundant peak | P | P | M23/M24/ M25/M26 | M23/M24/ M25/M26 | M23/M24/ M25/M26 |
| second most abundant peak | M13 * | M13 | M16/M17 | M18/M19/M20 | M16/M17 |
| third most abundant peak | M5 * | M5 | M18/M19/M20 | M16/M17 | M18/M19/M20 |